• U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes
• The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body
• The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced a new license agreement in relation to a gene therapy for both Type 1 and Type 2 diabetes
• The company’s novel infusion process using related gene therapy has shown statistically significant results in preclinical testing and Genprex anticipates a pending Phase I trial following the generation of sufficient preclinical data

Clinical-stage cancer and diabetes gene therapy developer Genprex (NASDAQ: GNPX) continues to expand its intellectual property portfolio for the company’s diabetes gene therapy program, recently announcing that it has entered into an exclusive license agreement related to a particular gene therapy for both Type 1 and Type 2 diabetes.

Specifically, the announcement involves a worldwide exclusive license to a patent application and related technology, and a worldwide non-exclusive license to use certain related know-how using the genes of the Pdx1 and MafA transcription factors controlled by a MafB promoter, as developed by the University of Pittsburgh (Pitt).

Genprex is developing technologies to administer disease-fighting genes that will provide new therapies in the fight against cancer and diabetes for large patient populations. In regard to the company’s diabetes approach, the Pdx1 and MafA genes are delivered directly to the pancreas through a novel infusion process (gene therapy candidates GPX-002 and GPX-003).

GPX-002 seeks a solution for type 1 diabetes, which most often appears in childhood or teen years and has no cure. In most cases, the body’s own immune system destroys the insulin-producing (islet) cells in the pancreas for some reason, slowing or stopping the production of vital sugar-regulating hormones (https://ibn.fm/14AW4).

GPX-002 changes alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to help them avoid being destroyed by the body’s immune system. Preclinical testing in mouse models and subsequently in non-human primates has produced statistically significant results to this effect.

GPX-003 seeks a solution for type 2 diabetes, which is more common in adults but similarly involves insufficient quantities of the sugar-regulating insulin hormone, although not as a result of attacks by the body’s immune system. Instead, muscle, fat and liver cells simply become resistant to insulin, and the pancreas fails to produce enough insulin to regulate sugars.

GPX-003 also uses a novel infusion process to deliver Pdx1 and MafA genes directly to the pancreas, which are expected to work by rejuvenating diminished beta cells to increase insulin expression. A Phase I clinical trial in diabetic patients is pending, following the generation of sufficient preclinical data (https://ibn.fm/1nO8Z).

“We are continuing to build a fortress of protection and a powerful intellectual property portfolio for our diabetes gene therapy program,” Genprex Chairman, President, and Chief Executive Officer Rodney Varner stated in the company’s news release about the new Pitt license (https://ibn.fm/mFZqN). “The addition of this license to MafB promoter technology expands and strengthens the potential for this novel, gene therapy to treat Type 1 and Type 2 diabetes.”

The company’s CMO, Mark Berger, MD, added, “What is exciting about this latest licensed technology is the early data suggests greater potency when combined with other previously licensed technologies and may be a particularly significant step forward in our construct optimization.”

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Ucore Rare Metals Inc. is demonstrating the rare earth feedstock refining capabilities of its proprietary RapidSX(TM) processing technology at an Ontario facility while preparing to build a commercial plant in Louisiana, developing a North America-based supply chain for critical tech metals
• Rare earth element (“REE”) processing is currently almost exclusively controlled worldwide by the People’s Republic of China, and governments as well as industry players are searching for solutions to develop rare earth sourcing not reliant on Chinese industry and its government’s policies
• Companies that have been involved in mining REEs have thus far encountered significant impediments to their efforts to refine the metals independent of China’s globe-dominating REE industries
• RapidSX is being developed as an advantageous alternative to the industry standard SX process for rare earth refining, expecting to show less environmental impact, faster production, and fewer resource needs, as well as independence from China’s supply chain

A recent Reuters report on the challenges facing rare earth (“REE”) processing companies outside of China underscores the potential market opportunity awaiting critical technology metals supply chain innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), as Ucore works to bring its proprietary North America-based REE processing technology online for commercial use.

Ucore is using a unique facility in Ontario, Canada to demonstrate the capability of its RapidSX(TM) solvent extraction process to bring REEs and other critical technology metals to market and do so in an environmentally sound way.

The company has acquired property in Louisiana, United States where it intends to begin construction on a commercial-scalable REE processing plant using RapidSX(TM) later this year.

The Reuters report (https://ibn.fm/aukNP) notes that economies around the world have been struggling to refine their own rare earths in order to “break China’s stranglehold on the key group of 17 metals needed for the clean energy transition.”

It highlights the frustrated efforts of two companies — MP Materials and Lynas — to take REEs they’ve mined and turn them into material for making magnets that are used across the globe in economically sweeping products such as Apple’s iPhone, Tesla’s Model 3 electric vehicle, and Lockheed Martin’s F-35 fighter jet.

The People’s Republic of China effectively controls the supply chain for REEs and other tech metals thanks to strategic buildup of its industries and pricing of its output over the past few decades, leading to estimates that the country is refining 89 percent of the world’s neodymium and praseodymium, which are key metals for EV magnets, and 99 percent of dysprosium, which is used for retaining magnetization at high temperatures, Reuters notes.

The European Union imports 98 percent of its REE supply from China, while the United States imports 78 percent of its supply from the Asian nation (https://ibn.fm/yyvJG).

Other companies each encountered distinct impediments to their efforts to develop REE sourcing that is not reliant on Chinese industry.  “The rare earths refining process can be very finicky,” University of Arizona mining and geological engineering department director Kray Luxbacker told Reuters. “There are just so many complex steps.”

Ucore is excited about its prospects in putting RapidSX(TM) to work. The company’s demonstration plant in Ontario is designed to provide a direct comparison between the RapidSX(TM) output and the output of the conventional SX process used by China and all other processors in the industry.

“Independent testing has shown that the innovative column-based RapidSX platform can separate rare earths nearly 10 times faster within a footprint that is about one-third the size required for the mixer-settler units used for traditional SX separation,” Alaska’s Metal Tech News reported earlier this year (https://ibn.fm/weW6R).

Ucore is also working with the U.S. Department of Defense (“DOD”) to demonstrate the potential of Rapid SX(TM), utilizing a $4 million grant from the federal government.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• SuperCom provides offender monitoring products and solutions under the best-of-breed PureSecurity Electronic Monitoring (“EM”) Suite
• The PureSecurity EM Suite includes the PureOne ankle bracelet, PureTag ankle bracelet, PureCom base station, PureTrack smartphone, PureProtect mobile phone application, PureBeacon radiofrequency (“RF”) device, and the PureMonitor cloud-based software
• A growing body of research supports home confinement with EM as an effective and appropriate alternative to imprisonment for lower-risk offenders
• Research shows that people assigned to home confinement with EM have similar or better outcomes than those who serve time in prison, as measured by future criminality
• By providing EM solutions, SuperCom is helping governments reduce overcrowding in prisons, lower recidivism, and improve public safety

When the U.S. federal government decided to implement home confinement under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, it considered, among others, the ability of home supervision and EM to enforce many of the restrictions and safeguards of a prison cell. The decision followed the March 2020 signing into law of the CARES Act, which allowed the federal Bureau of Prisons (“BOP”) to place individuals into home confinement during the official emergency period, which began January 31, 2020, and ended May 11 this year (https://ibn.fm/uppB0).

As of May 27, 2023, the BOP had placed 13,204 individuals into home confinement, with only 521 of those people being returned to secured custody. Of these, 296 were returned due to alcohol or drug use, 113 for technical violations, 90 for failing to remain at a designated location, and 22 for new criminal conduct. The early results of home confinement under the CARES Act are strong, according to a recent article in Niskanen Center (https://ibn.fm/B11b1).

These results contribute to a global body of research evidence that supports the thesis that home confinement is an effective and appropriate alternative to imprisonment for lower-risk offenders. Drawn from studies conducted in the U.S., Norway, Argentina, Australia, Germany, England and Wales, and France, the research evidence, the article says, shows that “people assigned to home confinement with electronic monitoring – either instead of prison or as a condition of release – have, at worst, similar outcomes to those who serve time in prison and, at best, significantly better outcomes, as measured by future criminality.” The article also points out that researchers ascribe substantial cost savings to home confinement.

“Finally, evidence overwhelmingly supports the idea that certainty of apprehension is the most important factor in criminal deterrence, and electronic monitoring substantially increases the probability of capture for any given offense,” the article continues. “Research has shown that offenders on monitoring are aware that authorities are tracking their location, and are aware that they are very likely to be caught should they commit a crime.”

Recognizing the effectiveness of EM in lowering recidivism rates and reducing prison overcrowding, governments are turning to companies such as SuperCom (NASDAQ: SPCB), a global secure solutions integrator and technology provider for governments and consumer-facing organizations worldwide.

SuperCom provides offender monitoring products and solutions under the best-of-breed PureSecurity EM Suite, which includes the PureOne all-in-one GPS tracking ankle bracelet, PureTag ankle bracelet, PureCom base station, PureTrack smartphone, PureProtect mobile phone application, PureBeacon radiofrequency (“RF”) device, and the PureMonitor software. The company combines two or more of these products to provide individual services such as GPS monitoring, home detention (house arrest) enforcement and monitoring, inmate monitoring, and domestic violence monitoring.

For instance, to provide its house arrest solution, the company pairs PureTag, a slim, lightweight, waterproof, and dustproof ankle bracelet with advanced tampering detection, with PureCom, a base station that communicates over LTE, Wi-Fi, and landline connectivity. The company then provides the PureMonitor software, which is used by law enforcement officers to manage these products and monitor offenders. The house arrest ecosystem of products enforces scheduled and spontaneous biometric authentication and minimizes the need for home visits (https://ibn.fm/WvhXj).

Similarly, SuperCom’s GPS Offender Tracking combines the PureTag bracelet with the PureTrack smartphone location capabilities and PureBeacon Bluetooth connectivity (https://ibn.fm/x7qbq), while the domestic violence monitoring solution pairs the PureTag bracelet with the PureProtect app and PureMonitor software (https://ibn.fm/zvT3E).

The company’s PureSecurity EM Suite has attracted a host of countries interested in improving public safety while reducing prison overcrowding and recidivism rates. Earlier this year, SuperCom announced it had launched a $3.6 million project with the national government of Finland to deploy SuperCom’s PureSecurity EM suite (https://ibn.fm/0sdWP). Shortly thereafter, the company announced that, together with its local partner, it had received a second order from Romania’s Ministry of Interior to deploy its PureSecurity EM Suite following successful completion of the first phase (https://ibn.fm/R2av0).

“The growing number of countries opting for advanced EM solutions highlights the increasing need for exceptional technology in this industry. We take pride in the fact that our innovative and proven technology is chosen repeatedly, allowing us to continue revolutionizing the EM industry as we enter new European countries,” commented SuperCom President and CEO Ordan Trabelsi in a news release announcing the project with the government of Finland.

With its growing backlog of orders and projects, SuperCom continues to solidify its position as a leader in the electronic monitoring market and a trusted partner to governments worldwide, according to Ordan. The company aims to continue providing its innovative and proven technology and services to help governments improve public safety while lowering recidivism, a result supported by a growing body of research evidence.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• The ADA reports that 37.3 million Americans had diabetes in 2019, and the number has been growing by an average 1.4 million each year
• 95% of Americans with diabetes are diagnosed with type 2 diabetes, which can lead to heart disease, stroke, kidney damage, and nerve damage when left untreated
• Lexaria’s DIAB-A22-1 pre-clinical diabetes study using DehydraTECH(TM)-CBD in obese diabetic-conditioned animals shows promising results, prompting the company to investigate for human trial

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical trial to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company’s pre-clinical diabetes study, DIAB-A22-1, in obese diabetic-conditioned animals, provided successful results and has driven Lexaria’s management to investigate whether animal improvements will be evidenced in humans.

Diabetes can impact various parts of the body, including the heart, kidneys, eyes, feet, and legs. The longer a person lives with the condition at high blood sugar levels, the more serious complications can become. Diabetes is manageable, but its impact on overall health is often underestimated.

According to the American Diabetes Association (“ADA”), 37.3 million Americans reported having diabetes in 2019. Of those 37.3 million, 28.7 million were diagnosed, and 8.5 million were not. Each year, the ADA reports an additional 1.4 million Americans are diagnosed with diabetes (https://ibn.fm/spkfX). When left untreated, diabetes can lead to complications, including heart disease, stroke, kidney damage, and nerve damage. “Non-alcoholic fatty liver disease (‘NAFLD’), which doctors historically have diagnosed in adults, is rapidly increasing in children, driven by the obesity epidemic” (https://ibn.fm/8mfbG).

More than 95% of the people diagnosed with diabetes fall into the category of Type 2 diabetes, which affects how the body uses sugar for energy. Over time, type 2 diabetes can cause serious damage to the body if it is not managed. Often preventable, factors that contribute to the development of type 2 diabetes are obesity, lack of exercise, and genetics (https://ibn.fm/D6g1v).

Lexaria designed DehydraTECH for formulating and delivering lipophilic drugs and active pharmaceutical ingredients. The benefits of DehydraTECH include faster drug delivery times, increased bioavailability, increased brain absorption, higher drug potency, reduced drug administration costs, masking tastes, and reduced use of sugars.

DehydraTECH is suitable for various product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, topicals, and over-the-counter pills, capsules, tablets, and oral suspensions. Lexaria has already shown value in the hypertension and nicotine pouch industries through the use of its DehydraTECH formulations.

Lexaria’s DIAB-A22-1 study in obese diabetic-conditioned animals utilized its DehydraTECH-CBD formulation, which showed an ability to reduce animal blood sugar levels – warranting additional investigation. Lexaria reported:

• Lowered blood glucose levels by 19.9% (p<0.05)
• Lowered overall body weight by 7% sustained over eight weeks
• Witnessed a statistically significant increase in locomotor activity (p<0.05)
• Lowered triglyceride levels by more than 25% (p<0.007)
• Lowered blood urea nitrogen levels by 27.9% (p<0.001)

The company is very interested in discovering if a similar formulation might effectively control human blood sugar levels – strongly suggesting that DehydraTECH-CBD may be a potential solution for treating diabetes and its complications in humans.

Lexaria intends to conduct the study, which is currently being designed, at the same medical research hospital in Europe that it used for its recent human clinical hypertension studies. The cost-effective approach allows Lexaria to complete the most research possible at a fraction of the cost of US-based registered study programs. Once the study has been designed and approved, Lexaria will provide additional information, including timelines and study details, as they become available.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• RJDG subsidiary IOSoft Systems Inc. provides billing, payment, and healthcare claims adjudication solutions for healthcare payers and providers
• IOSoft suite of modular cloud-based SaaS solutions integrates seamlessly with legacy or existing systems, can be used separately or integrated as a complete claims and payment management system
• IOSoft Systems operates as separate business unit under RJDG Healthcare Services division, other divisions include Earthlinc Environmental Solutions and Silex Holdings Inc.

IOSoft Systems, the software division of RJD Green (OTC: RJDG), a holding company, provides proprietary cloud-based SaaS and IT support for small-cap companies with a focus on medical billing, healthcare claims adjudication, and electronic payment solutions for healthcare payers and providers. The Company’s suite of modular software products offers comprehensive pricing and claims payment tools with options to use solutions individually or together as a complete claims and payment management system.

IOSoft’s technology integrates seamlessly with legacy or existing systems used by healthcare organizations, including major health insurance carriers, hospitals, physicians, and clearinghouse companies. The Company’s ioSoft LinkUP(TM) additionally serves as a robust communication interface, enabling users to access their ID cards, view claim information, and update their enrollment 24/7 on any connected iOS or Android device.

RJD Green recently announced that IOSoft Systems secured a contract to customize ioSOFT Suites and provide IT support for the RailPro Group, a consulting and marketing team focused on energy-related companies and retail marketing (https://ibn.fm/RbIr8). “We are pleased to see IOSoft creating initial contracting in custom software and IT support for the small-cap business sector,” said RJD Green management. “We feel this sector creates an excellent growth opportunity for affordable and functional custom software platforms specifically for the individual client’s needs.”

RJDG focuses on acquiring and managing assets and companies in three divisions. These include RJD Green Healthcare, which owns IOSoft Systems, Silex Holdings Inc., and Earthlinc Environmental Solutions.

Silex Holdings Inc. acquires and manages high-growth assets and commercial enterprises in industrial contracting, building material products, and construction services. Silex Interiors, the Company’s first acquisition, manufactures, distributes, and installs countertops, cabinets, and associated bath and kitchen products with the aim of filling a market niche between large enterprises like Home Depot and local contractors.

Earthlinc Environmental Solutions promotes green technologies with a focus on solving ecological issues. The division’s first acquisition, Animal Waste Management, develops patented technology to process waste on commercial chicken and hog farms with support from the University of Arkansas and the Missouri Department of Natural Resources.

Ron Brewer, CEO of RJD Green, brings extensive leadership experience from public and private companies in all three industries served by the Company’s divisions. COO Jerry Niblett leverages nearly two decades of oil and gas sector expertise, including roles at Dominion Energy, Texaco, Sunoco Pipeline LP, and Shell. John Rabbitt completes the leadership team as CFO, bringing experience from Fortune 500 firms, including PepsiCo, Pillsbury, MEI Corp, and Ernst and Ernst.

Based in Tulsa, Oklahoma, RJD Green Inc. acquires and manages assets in the healthcare technology, environmental, and industrial contracting and building material spaces. With a solid track record of success, the Company’s leadership team leverages decades of industry knowledge and a robust business network to fast-track growth and profitability for each asset under its divisions.

For more information, visit the company’s website at www.RJDGreen.com.

NOTE TO INVESTORS: The latest news and updates relating to RJDG are available in the company’s newsroom at https://ibn.fm/RJDG

Financial analysts, savvy investors, business owners, researchers, and pioneers, are invited to attend Alternative Products Expo to be held at the World Market Center, Las Vegas from September 14-16, 2023. Las Vegas plays host to thousands of esteemed events every year, and there are several reasons for this: state-of-the-art hospitality, top-notch facilities, year-round sunshine, and world-class dining and entertainment options. Featuring one-of-a-kind nightlife, the city never fails to provide a memorable experience for the attendees.

Alternative Products Expo (AltPro Expo) promises to deliver unique networking opportunities for customers and businesses alike. The highly anticipated event has earned a reputation for offering an incredible platform for business owners to showcase their unique and sustainable products. As the countdown for this innovative Expo begins, attendees can expect an unmatched experience packed with actionable insights from the industry leaders.

Exciting Opportunities for Forward-Thinking Businesses

Pioneered by a group of socially responsible entrepreneurs, the Alternative Products Expo is committed to connecting revolutionary businesses with health-conscious customers. The expo will feature a wide range of eco-friendly and innovative products, ranging from plant-based foods, and renewable energy technologies, to sustainable packaging solutions and ethical fashion items. They will witness innovative demos and learn of the latest product launches that will shape a sustainable future and reduce the environmental footprint at a global level.

The AltPro Expo provides customers with a unique opportunity to buy products that contribute to an eco-friendly planet. The organizers will implement sustainable practices throughout the Expo to ensure the targeted audience aligns with their values. Attendees will get a unique opportunity to network with like-minded entrepreneurs and potential investors who will share their passion for innovation. By attending thought-provoking seminars and panel discussions, they will get insights into the latest trends and best practices in the alternative products industry.

To learn more, please visit https://ibn.fm/21jUz.

BREATHE!, a historic new tech event that focuses on the emerging technologies that continue to revolutionize the way businesses and communication are conducted worldwide, is proud to announce this year’s BREATHE! Convention. The event, scheduled for September 13-15, 2023, at The Expo @ World Market Center Las Vegas, provides a platform for exhibiting, networking, and speaking opportunities, for individuals and organizations within the emerging tech ecosystem.

The event targets a diverse group of attendees, ranging from developers to investors, enthusiasts, and researchers, to discuss the latest developments and trends in emerging technologies while also exploring numerous collaborative and community-driven efforts. More than 5,000 attendees are anticipated to grace the event with more than 80 educators and subject matter experts expected to lead speaking seminars, fireside chats, and panel sessions. BREATHE! is designed to create opportunities encompassing education, experience, and entertainment, delivering a one-of-a-kind convention.

BREATHE! Convention’s vision encompasses some incredible and often unexplored aspects of the emerging tech industry, including:

• Identifying market trends
• Revolutionizing the industry
• Developing new use cases

These crucial aspects of the emerging tech industry are brought to light through a diverse array of speaking seminars, panel sessions, and fireside chats, where educators and subject matter experts deliver important insights and experiences on Web3, Blockchain, AI technologies and applications, and more. This community-driven lineup of educators also covers topics such as decentralized finance (“DeFi”), non-fungible tokens (“NFTs”), as well as the future of the Web3 ecosystem. The latest list of speakers is available for viewing at: https://www.breatheconvention.com/speakers-list

BREATHE! Convention’s vision is achieved through networking opportunities, with event spotting workshops, panel discussions, and networking mixers, all designed to help attendees connect and build relationships. In addition, attendees will see the latest emerging technologies and products in action in the exhibit hall, where attendees have access to live demonstrations of decentralized applications (“dApps”), smart contracts, blockchain-based games, and more.

BREATHE! Convention is one of the first ever emerging tech conventions approved by The Expo @ World Market Center Las Vegas, that has a prime focus on community, networking, and mass adoption of game-changing technology for professionals from all walks of life. Backed by passionate, community-involved investors and collaborators, and built on education, experience, and entertainment through the power of emerging tech, this event lives true to its core narrative: “Connecting Ever-Expanding Possibilities.”

BREATHE! Convention is powered by Metakeep and NFT-TiX

To learn more, please visit https://ibn.fm/567CI

• GolfLync has tapped and fulfills a confirmed need in a strong market, like the most successful fast-growing companies that have come before it
• GolfLync does a superior job of engaging and bringing together the expanding golf community, using intelligent technology with a user-friendly interface
• Remarkable membership growth, a far above average conversion rate, and high social media ratings, point to a unique opportunity for investors as well as golf lovers

Usually defined as a startup that is privately owned with a valuation that exceeds $1 billion, a unicorn is the epitome of spectacular growth. Although being a unicorn doesn’t guarantee permanent success, the most famous former unicorns, such as Google (NASDAQ: GOOGL), Facebook (NASDAQ: META), and Airbnb (NASDAQ: ABNB), now have astronomical market caps, with Google’s topping out at over $1.5 trillion. Every one of them started out small, but with an idea that filled a real need, fueling rapid growth and investment. In particular, social media apps that empower the building of specialized online communities can soar on word-of-mouth alone.

GolfLync is soaring due to its unique and feature-strong ability to bring together people who love golf, a sport that is experiencing a post-pandemic revival, and a market that was already listed at $26.1 billion in 2022 (26 Glorious Golf Industry Statistics [2023]: How Big Is The Golf Industry – Zippia). The app (available as a free download on the Apple App Store and the Google Play Store) is powered by an intelligent algorithm that brings golfers together based upon a balanced range of factors, including handicap, preferred playing style, and location, along with various related interests and specifications. The app readily supports everything from matching individual partners to building large and diverse groups called “Virtual Golf Clubs”(TM). These GolfLync VGCs are becoming especially popular, and now spread around the country.

GolfLync CEO Noah DiPasquale says “It basically operates like Tinder for golfers”, while Michael Quiel, Co-Founder, summed it up: “Our commitment to providing a user-friendly and feature-rich platform has driven the exceptional growth and engagement we are witnessing.” According to the company, GolfLync has seen a 15x growth in membership in just the past 4 months. In addition, GolfLync has a social media conversion rate greater than 52%, compared to the average conversion rate of less than 33%, and has now reached the 75th percentile for user conversions as shown in the Apple Store. The GolfLync platform currently exceeds 200 ratings on the Apple App store with 5-star average.

You can download the GolfLync app using the following links:

• Android: GolfLync – Apps on Google Play 
• iPhone: ‎GolfLync

For more information about GolfLync, visit the company’s website at www.GolfLync.com.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Genprex recently received orphan drug designation for its lead drug candidate REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid) for the treatment of small cell lung cancer (“SCLC”)
• The company also celebrated receipt of its third Fast Track Designation (“FTD”), granted by the FDA, this time for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with extensive stage small cell lung cancer (“ES-SCLC”)
• The orphan drug designation (“ODD”) in combination with the FTD is an indication of the great need for better treatment options for patients with ES-SCLC, and non-small cell lung cancer (“NSCLC”), according to Genprex President, Chairman, and CEO Rodney Varner
• With the receipt of the latest FTD and the orphan drug status, Genprex is looking forward to initiating the Acclaim-3 clinical trial, planned for the fourth quarter of 2023

Genprex (NASDAQ: GNPX), a clinical-stage company developing life-changing gene therapies for patients with cancer and diabetes, recently celebrated an important milestone: the award of an orphan drug designation. The company announced August 10 that the United States Food and Drug Administration (“FDA”) had granted Orphan Drug Designation (“ODD”) to its lead drug candidate, REQORSA(R) Immunogene Therapy (quratusugene ozeplasmid), for the treatment of small cell lung cancer (“SCLC”) (https://ibn.fm/J4gpJ).

The FDA grants orphan drug status to a drug or biological product that prevents, diagnoses, or treats a rare disease or condition as part of the agency’s efforts to prioritize the development and evaluation of new treatments for rare diseases (https://ibn.fm/0PN7j). The ODD grants a sponsor – in this case, Genprex – incentives such as tax credits for qualified clinical trials and an exemption from user fees. Perhaps most importantly, the orphan drug designation grants potential seven-year exclusivity post-approval. The global SCLC therapeutics market is projected to grow at a CAGR of 12.3% from $5.12 billion in 2022 to $16.33 billion by 2032 (https://ibn.fm/y50nf).

The Orphan Drug Act (“ODA”) of 1983 defines rare diseases as those affecting “less than 200,000 persons in the United States.”  The FDA interprets this to mean that the prevalence of the disease, that is the number of people affected by the disease at a particular point in time, must be less than 200,000.  This is different than the incidence of the disease, which is the number of people newly diagnosed with SCLC during the course of a year (https://ibn.fm/cpEOA).

Based on the orphan drug definition SCLC is classified as a rare disease because the prevalence of SCLC is less than 200,000 cases in the US. The condition accounts for 13-15% of all lung cancer cases, and in the United States, about 238,440 adults will be diagnosed with lung cancer in 2023. The condition also presents a poor prognosis, partly because a majority of people – more than 60% – with SCLC are diagnosed after the cancer has spread outside the lung (https://ibn.fm/F7jpN). In such cases, the condition is known as extensive-stage SCLC (“ES-SCLC”).

Patients with ES-SCLC are given combination chemotherapy as the first-line treatment, with varying overall response rates of 44-78% and median progression-free survival (“mPFS”) that ranges between 4.3 and 5.7 months, depending on the selected combination (https://ibn.fm/gyNaW). Patients also undergo maintenance therapy, an ongoing cancer treatment, after the initial response to the first recommended treatment. The mPFS for patients receiving Genentech, Inc.’s Tecentriq(R) as maintenance treatment is only 2.6 months from the start of maintenance treatment, suggesting a substantial need for improvement in maintenance therapy, according to Genprex.

Genprex’s efforts to meet this need received a boost in June 2023 when the FDA granted Fast Track Designation (“FTD”) for REQORSA Immunogene Therapy, in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment (https://ibn.fm/wsBrh).

“We are excited to receive Orphan Drug Designation from the FDA for REQORSA for patients with SCLC,” commented Rodney Varner, President, Chairman, and CEO of Genprex. “This FDA Orphan Drug Designation in combination with our recently received FDA Fast Track Designation underscores the great need for better treatment options for patients with SCLC, ES-SCLC, and non-small cell lung cancer.”

Genprex’s lung cancer programs now have three FDA Fast Track Designations. In January 2020, the company announced that the FDA had granted an FTD for REQORSA in combination with AstraZeneca’s Tagrisso(R) for patients with NSCLC whose condition progressed after treatment with Tagrisso (https://ibn.fm/aSxQG). Later, in January 2022, the company announced it had received an FTD for REQORSA Immunogene Therapy in combination with Merck & Company’s Keytruda(R) in patients with NSCLC whose disease progressed after treatment with Keytruda (https://ibn.fm/L7Z1S).

With the receipt of the latest FTD and the orphan drug status, Genprex is looking forward to initiating the Acclaim-3 clinical trial, expected in the fourth quarter of 2023. Acclaim-3 is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• GEMXX recently announced that new investments had strengthened its financial position and would allow it to attract further investment over the next 12 months
• The announcement followed the acquisition of a 50% ownership stake in Crazy Horse Mining Inc., whose assets include a 100% interest in the Snow Creek and Rosella Creek gold projects in British Columbia
• Initial production results on the Snow Creek site prop GEMXX to scale up gold production, having announced plans to ramp up processing to approximately 1,000 cubic yards of gold-bearing ore per day

GEMXX (OTC: GEMZ), a publicly traded vertically integrated company specializing in producing and distributing gemstones and jewelry globally, using its own gold and Ammolite mining resources, is already seeing a return on key investments. Stemming from its ambitious growth plan, the company has ventured into untapped markets, exploring acquisitions and further integrating critical services, distribution networks, and retail outlets into its fold, all of which have shown great promise from a return on investment (“ROI”) standpoint.

As the only public company doing what it does, specifically engaging in Ammolite mining worldwide, GEMXX represents several firsts, including charting the path for other players in its industry. As it owns its reserves, the company currently enjoys a significant cost-saving edge over other producers in the gemstone and jewelry market, a leverage that allows it to explore other ambitious investment opportunities.

Just recently, GEMXX announced that new investments had strengthened its financial position, providing new energy to fulfill its growth strategy for the year. It also noted that the strengthened financial position would aid in situating the company’s market positioning, allowing it to attract further investment over the next 12 months. This followed the acquisition of a 50% ownership stake in Canadian gold mining company Crazy Horse Mining Inc., with an estimated recovery rate of 100,000 ounces of gold from its sites.

“We are tremendously pleased with the development of the Company over the past several months, and we are extremely excited for the anticipated growth,” noted Jay Mauli, GEMXX’s Founder, Chairman and CEO (https://ibn.fm/DoPh9).

Crazy Horse’s assets include a 100% interest in the Snow Creek and Rosella Creek gold projects, both spread across more than 700 acres in British Columbia. On August 15, GEMXX announced the completion of its first clean-out and recording of gold production on the site for the 2023 mining season. A 4,500-cubic-yard sample of gold-bearing surface ore was processed, ultimately providing a “positive indication of the resource potential on the property” (https://ibn.fm/DSrjg).

Most notably, the initial production results yielded 38.73 ounces of gold from 4,500 cubic yards of surface material, amounting to 0.86 ounces per 100 cubic yards. These results prop GEMXX to scale up gold production, having announced plans to ramp up processing to approximately 1,000 cubic yards of gold-bearing ore daily.

Through investments such as these, coupled with executing its overall business plan, GEMXX is positioning itself as a market leader. Additionally, it is inching closer to being fully integrated from mine to market while readying itself for any economic condition. Most importantly, these moves indicate the company’s commitment to creating shareholder value.

“We intend to do everything necessary to drive shareholder value,” noted Mr. Mauli.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/scLU3) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ